Skip to content

Viemed Healthcare, Inc. VMD Change in Deferred Revenue

Change in Deferred Revenue at other companies

Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$214K-91.5%
iRadimed logo
iRadimedIRMD
$305K-44.2%
HealthStream logo
HealthStreamHSTM
$17.9M+2.5%
AMN Healthcare logo
AMN HealthcareAMN
-$4.41M-312%
Doximity logo
DoximityDOCS
-$33.82M-37.3%

Other financials

Income statement

See full
Revenue$75.4M+27.5%
Gross profit$42.8M+28.7%
Operating income$4.3M+11.8%
Net income$2.6M-1.6%
EPS (diluted)$0.060.0%

Balance sheet

See full
Cash & equivalents$9.8M-3.9%
Total debt$12.4M+84.0%
Total equity$143.9M+6.8%
Total assets$197.4M+10.8%

Cash flow

See full
Operating cash flow$8.1M+183%
CapEx$6.7M-56.6%
Free cash flow$1.4M+111%

Valuation

See full
Market cap$448.16M+71.3%
Enterprise value$450.83M+74.6%
P/E30.1×+8.8×
P/S1.6×+0.4×

Profitability

See full
Gross margin57.6%-1.1pp
Operating margin8.2%-0.2pp
Net margin5.2%-0.1pp
FCF margin9%

Returns & leverage

See full
Return on equity10.7%+0.9pp
Debt / equity0.1×0.0×
Current ratio1.2×-0.2×

Where this comes from

Reported directly by Viemed Healthcare, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Viemed Healthcare, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viemed Healthcare, Inc.'s change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viemed Healthcare, Inc.'s change in deferred revenue?
Viemed Healthcare, Inc. (VMD) reported change in deferred revenue of -$41K in Q1 2026.
How has Viemed Healthcare, Inc.'s change in deferred revenue changed year-over-year?
Viemed Healthcare, Inc.'s change in deferred revenue decreased by 140.6% year-over-year, from $101K to -$41K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.